Clinical trial
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in…
NCT00216372 · Ipsen, Industry · Completed
Key facts
| NCT number | NCT00216372 |
|---|---|
| Title | Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis |
| Official title | Phase III, Multicentre, Randomised, Double-blind, Comparative Study to Assess the Efficacy and Safety of Lanreotide 30 mg Versus Placebo as a Palliative Treatment of Clinical Symptoms Associated With Intestinal Obstruction Due to Peritoneal Carcinomatosis in Inoperable Patients. |
| Lead sponsor | Ipsen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Intestinal Obstruction, Carcinoma, Peritoneal Neoplasms |
| Intervention type | Drug, Other |
| Interventions | Lanreotide (microparticle formulation), Placebo |
| Enrollment | 80 |
| Start date | Sep 1, 2003 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 5, 2020 |
| Countries | Belgium, France, Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: